focus -WSS

focus

author：Wikipedia 2025-09-30 00:50:27 - browse：3579

Photograph of Glaxo Smith Kline headquarters in London for a story on multiple myeloma cancer treatment ahead of the 2024 ASCO conference — JUSTIN TALLIS/AFP via Getty Images

LONDON — The resurrection of a GSK blood cancer drug — which the company withdrew from the U.S. market not even two years ago after it failed a key study — is taking its next step forward.

At the annual American Society of Clinical Oncology conference in Chicago, researchers on Sunday are presenting trial data showing that the drug, called Blenrep, outperformed a standard therapeutic approach when combined with another medicine in patients with multiple myeloma. It’s the second positive study for Blenrep in myeloma in recent months, and next up could be a return to regulatory agencies to get the drug re-approved.

In an interview, Hesham Abdullah, GSK’s oncology research leader, said the company planned to submit Blenrep to regulators by the end of the year.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the pharma industry — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medicare details structure of new drug price negotiation program
Next article： Quicker fix for pulse oximeters urged during FDA public meeting

WSS

Cognito secures funding to test medical device for Alzheimer's

Deliver public health messages at the right time

Most antidepressants don't work on kids, teens, study finds

Welsh Carson private equity firm escapes from FTC antitrust case

AI for drug discovery: Experts on separating hype from reality

Commercial surrogacy can be ethical, despite pope’s claims

focus

focus

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the pharma industry — by subscribing to STAT+.

focus

Wildfire smoke exposes gaps in outdoor worker protections

As health system earnings go up, health insurance stocks go down

Drug repurposing or repositioning? The language matters

In a test for AI, buzzy startup Insitro inks drug discovery deal with Gilead

ChatGPT in medicine: STAT answers readers' burning questions

Empower primary care with adequate payments and technology

After affirmative action ruling, medical educators look to 'holistic review'

GSK’s asthma push continues as drug succeeds in Phase 3 trials

Duchenne breakthrough therapy leaves behind pioneering families

Is it ever OK for doctors to lie to their patients?

focus

The effects of a landmark ruling on DNA ownership are becoming clearer

Biden administration opens offers in Medicare drug price negotiations

ARCH Venture Partners is raising $3 billion for a life sciences fund

Some dementia cases could be undiagnosed liver disease

SAMSHA loosens regulations on methadone treatment centers

General Catalyst, Summa Health deal will turn on physician buy

Wikipedia

hotspot

hotspot

explore